A Paradigm Shift in First-Line Treatment Can Have Many Implications For Second-Line Treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Paradigm Shift in First-Line Treatment Can Have Many Implications For Second-Line Treatment

Published:2024-02 Issue:2 Volume:19 Page:350
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Nishimura Tadashi^ORCID

Publisher

Elsevier BV

Reference5 articles.

1. Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage SCLC in the era of immunotherapy;Torasawa;J Thorac Oncol,2024

2. Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer;Imai;Investig New Drugs,2022

3. Efficacy and safety of amrubicin in small cell carcinoma previously treated with immune checkpoint inhibitors and chemotherapy;Nishimura;Cancers,2022

4. Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients;Kushiro;Transl Lung Cancer Res,2022

5. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: a retrospective multicenter study (TOPGAN 2021–01);Uematsu;Thorac Cancer,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3